Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Mitomics Inks US Marketing Deal for Prostate Test

Mitomics Inks US Marketing Deal for Prostate Test

Feb 14, 2012

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mitomics today announced that it has signed a non-exclusive agreement with LabMD to market its Prostate Core Mitomic Test in the US.

The PCM test is based on mitochondrial DNA and identifies a biomarker that indicates the presence of cancerous cells in prostate biopsy tissue. Thunder Bay, Ontario-based Mitomics said the test has a sensitivity of 84 percent with a negative predictive value of 91 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Maybe Not the Source

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

And Now Machines

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

Not Making It Clearer

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

Nature Papers Describe Genome Aggregation Database, Mendelian Randomization Method

In Nature this week: the largest known collection of human genetic variants, and more.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.